BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 19250191)

  • 1. 5alpha-reductase isozymes and androgen actions in the prostate.
    Zhu YS; Imperato-McGinley JL
    Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status.
    Torres JM; Ruiz E; Ortega E
    Prostate; 2003 Jun; 56(1):74-9. PubMed ID: 12746849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
    Titus MA; Gregory CW; Ford OH; Schell MJ; Maygarden SJ; Mohler JL
    Clin Cancer Res; 2005 Jun; 11(12):4365-71. PubMed ID: 15958619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats.
    Sánchez P; Torres JM; Vílchez P; Del Moral RG; Ortega E
    IUBMB Life; 2008 Jan; 60(1):68-72. PubMed ID: 18379994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Region-specific expression of androgen and growth factor pathway genes in the rat epididymis and the effects of dual 5alpha-reductase inhibition.
    Henderson NA; Cooke GM; Robaire B
    J Endocrinol; 2006 Sep; 190(3):779-91. PubMed ID: 17003279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ androgen producing enzymes in human prostate cancer.
    Nakamura Y; Suzuki T; Nakabayashi M; Endoh M; Sakamoto K; Mikami Y; Moriya T; Ito A; Takahashi S; Yamada S; Arai Y; Sasano H
    Endocr Relat Cancer; 2005 Mar; 12(1):101-7. PubMed ID: 15788642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of type I and type II 5alpha-reductase isoenzymes in prostate cancer tissues].
    Ye L; Zhang Y; Fang Z
    Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(24):1504-7. PubMed ID: 16200776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue.
    Makridakis N; Akalu A; Reichardt JK
    Oncogene; 2004 Sep; 23(44):7399-405. PubMed ID: 15326487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
    Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
    J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview on 5alpha-reductase inhibitors.
    Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
    Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin.
    Pelletier G; Luu-The V; Huang XF; Lapointe H; Labrie F
    J Urol; 1998 Aug; 160(2):577-82. PubMed ID: 9679931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
    Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid 5alpha-reductase isozymes in the adult female rat brain: central role of dihydrotestosterone.
    Torres JM; Ortega E
    J Mol Endocrinol; 2006 Apr; 36(2):239-45. PubMed ID: 16595696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
    Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
    J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas.
    Bonkhoff H; Stein U; Aumüller G; Remberger K
    Prostate; 1996 Oct; 29(4):261-7. PubMed ID: 8876709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M; Bartsch W; Thomsen M; Voigt KD
    J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-organizing molecular field analysis on pregnane derivatives as human steroidal 5alpha-reductase inhibitors.
    Aggarwal S; Thareja S; Bhardwaj TR; Kumar M
    Steroids; 2010 Jun; 75(6):411-8. PubMed ID: 20170668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
    Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
    Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.